Enterprise Value
72.24M
Cash
312.9M
Avg Qtr Burn
-4.116M
Short % of Float
4.46%
Insider Ownership
0.52%
Institutional Own.
29.92%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Icosapent Etheyl (generic Vascepa) Details Triglycerides, Heart disease, Cardiovascular disease | Approved Update | |
Vascepa (icosapent ethyl) Details Triglycerides, Heart disease, Cardiovascular disease | Approved Quarterly sales | |
Vascepa (icosapent ethyl) Details Infectious disease, COVID-19 | Failed Discontinued |